These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27626890)

  • 1. An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union.
    Meier A; Faulkner SD; Schoonderbeek C; Jong B; Kung J; Brindley D; Barker R
    Clin Pharmacol Ther; 2016 Dec; 100(6):743-753. PubMed ID: 27626890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raising the Barriers to Access to Medicines in the Developing World - The Relentless Push for Data Exclusivity.
    Diependaele L; Cockbain J; Sterckx S
    Dev World Bioeth; 2017 Apr; 17(1):11-21. PubMed ID: 26818105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
    Allard Soto R
    Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union:
    't Hoen EFM; Boulet P; Baker BK
    J Pharm Policy Pract; 2017; 10():19. PubMed ID: 28670455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Between pharmaceutical patents and European patients: is a compromise still possible?
    Garattini L; Padula A
    Expert Opin Ther Pat; 2017 Oct; 27(10):1073-1076. PubMed ID: 28671001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research on the pharmaceutical intellectual property protection and supervision of pharmacy administration.
    Xu Z; Chen W
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1081-1087. PubMed ID: 28671085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Compulsory Licensing Bad for Public Health? Some Critical Comments on Drug Accessibility in Developing Countries.
    Guennif S
    Appl Health Econ Health Policy; 2017 Oct; 15(5):557-565. PubMed ID: 28120166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Looking inward: regional parallel trade as a means of bringing affordable drugs to Africa.
    Buckely M
    Seton Hall Law Rev; 2011; 41(2):625-69. PubMed ID: 21739760
    [No Abstract]   [Full Text] [Related]  

  • 11. A study of pharmaceutical data exclusivity laws in Latin America: is access to affordable medicine threatened?
    Cartagena RG; Attaran A
    Health Law J; 2009; 17():269-96. PubMed ID: 20608321
    [No Abstract]   [Full Text] [Related]  

  • 12. Asserting the primacy of health over patent rights: a comparative study of the processes that led to the use of compulsory licensing in Thailand and Brazil.
    Rosenberg ST
    Dev World Bioeth; 2014 Aug; 14(2):83-91. PubMed ID: 24750542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
    Son KB; Lee TJ
    Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges to sovereign ambitions: forces of convergence and divergence within the global pharmaceutical sector and the UK's withdrawal from the European Union.
    Wright JSF; Doukas D
    Health Econ Policy Law; 2021 Jul; 16(3):256-272. PubMed ID: 32583755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent law--balancing profit maximization and public access to technology.
    Beckerman-Rodau A
    Columbia Sci Technol Law Rev; 2003; 4():E1. PubMed ID: 15977333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protecting the rights of producers original medicines.
    Pashkov V; Kotvitska A; Noha P
    Wiad Lek; 2017; 70(4):834-837. PubMed ID: 29064813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ethics of intellectual property rights in an era of globalization.
    Shah AK; Warsh J; Kesselheim AS
    J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
    Ghosh S
    Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic patent protection in the pharmaceutical and biotechnology industries.
    Nunnally AC; Webster CJ; Brown SA; Cohen GA
    Community Genet; 2005; 8(4):209-16. PubMed ID: 16244474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.